CFM
IRWD icon

Catalyst Funds Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Catalyst Funds Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,340
Closed -$9.57K – 580
2025
Q2 		$9.57K Sell
13,340
-335,500
-96% -$263K ﹤0.01% 429
2025
Q1 		$513K Buy
348,840
+338,340
+3,222% +$806K 0.13% 184
2024
Q4 		$46.5K Buy
+10,500
New +$42.6K 0.01% 281

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Catalyst Funds Management's IRWD Position: Q3 2025 in Review

Catalyst Funds Management sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2025, closing a stake of 13,340 shares — an estimated $9.57K sold.

Catalyst Funds Management first reported a position in IRWD in Q4 2024 and held it in 3 quarters. The position peaked at $513K in Q1 2025. 166 funds tracked by Wall St. Rank hold IRWD as of Q3 2025.

  • Catalyst Funds Management reported no remaining Ironwood Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 13,340 Ironwood Pharmaceuticals shares in Q3 2025, an estimated $9.57K.
  • Catalyst Funds Management first reported a position in Ironwood Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Ironwood Pharmaceuticals position peaked at $513K in Q1 2025.
  • 166 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.